QGC101 program


Despite some medical breakthroughs, mortality rate due to heart failure remains high: about 50% of the persons diagnosed with heart failure die within 5 years. There is therefore an urgent need to develop new pharmacological treatments for heart failure. Quantum Genomics intends to demonstrate the therapeutic benefit of BAPAIs for the treatment of heart failure.

Exploratory works carried out by the team led by Dr. Catherine Llorens-Cortès in collaboration with the team of Pr. F. Leenen at the Heart Institute of Ottawa (Canada) have demonstrated that an hyperactivity of the brain renin-angiotensin system as well as that of the sympathetic system could contribute to the progressive remodelling and dysfunction of the heart after a myocardial infarction. When administered to rats which have undergone myocardial infarction, QGC001 was found to inhibit APA and the production of AngIII at the level of the brain, to reduce the activity of the sympathetic nervous system and thus to improve the the cardiac left ventricle function of the animals.

The QGC001 product appears as a new promising therapeutic agent for the treatment of heart failure both in Human and animals.

Within our QGC101 programme for heart failure, at the end of June 2016 we initiated our first phase IIa study in human. This Pan-European randomized, double-blind study, called QUID HF (QUantum genomics Incremental Dosing in Heart Failure) plans to enroll 75 patients at approximately 10 university medical centres in 8 countries.